董事会关于独立董事独立性自查情况的专项报告 康芝药业股份有限公司 康芝药业股份有限公司 根据《上市公司独立董事管理办法》《深圳证券交易所创业板股票上市规则》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等要求，康芝药业股份有限公司(以下简称"公司")董事会，就公司在任独立董 事郑欢雪、吴清和、张继承、方灿辉的独立性情况进行评估并出具如下专项意见: 经核查独立董事郑欢雪、吴清和、张继承、方灿辉的任职经历以及签署的相 关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主 要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能 妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董事 管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》中对独立董事独立性的相关要求。 特此公告。 董 事 会 2025 年 4 月 25 日 1 ...

2、是否存在影响独立性的情况说明 2024年度，作为公司独立董事，本人及我的直系亲属、主要社会关系均不 在公司或其附属企业任职，不直接或间接持有公司股份，不在直接或间接持有 公司已发行股份5%或以上或公司前五名股东单位任职，不在公司控股股东、实 际控制人的附属企业任职，没有与公司及其控股股东、实际控制人或其附属企 -4- 业有重大业务往来。本人不曾为公司及其控股股东、实际控制人或其附属企业 提供财务、法律、咨询、保荐等服务。本人符合《上市公司独立董事管理办法》 第六条规定的独立性要求，并在履职中保持客观、独立的专业判断，不存在影 响独立性的情况。 各位股东及股东代表： 本人作为康芝药业股份有限公司（以下简称"公司"）的独立董事，在任 职期间严格按照《公司法》《证券法》《上市公司独立董事管理办法》《深圳 证券交易所上市公司自律监管指引第2号——创业板上市公司规范运作》《公司 章程》《独立董事工作制度》等相关法律、法规、规章的规定和要求，在2024年度 工作中，诚实、勤勉、独立地履行职责，积极出席相关会议，认真审议董事会各项 议案，充分发挥了独立董事及各专业委员会的作用。一方面，严格审核公司提交董 事会的相关事项 ...

各位股东及股东代表： （二）独立性说明 在担任公司独立董事期间，本人未在公司担任除独立董事以外的任何职务， 也未在公司主要股东单位担任任何职务，与公司以及主要股东之间不存在妨碍 本人进行独立客观判断的关系，不存在影响独立董事独立性的情况，符合《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第2号—— -4- 创业板上市公司规范运作》等法律、法规、规章和规范性文件中关于独立董事 独立性的相关要求。 本人作为康芝药业股份有限公司（以下简称"公司"）的独立董事，于 2024年6月28日经公司2023年度股东大会审议表决通过正式上任。根据《公司法》 《证券法》《上市公司治理准则》《上市公司独立董事管理办法》等相关法律、 法规及《公司章程》《独立董事工作规则》等公司制度的规定，任职期内，定 期了解检查公司经营情况，认真履行了独立董事的职责，恪尽职守，勤勉尽责， 积极出席相关会议，认真仔细审阅会议议案及相关材料，积极参与各项议题的 讨论并提出了许多合理建议，充分发挥了独立董事作用，努力维护了公司整体 利益和全体股东特别是中小股东的合法权益。根据《上市公司独立董事管理办 法》《深圳证券交易所上市公司自律监 ...

证券代码：300086 证券简称：康芝药业 公告编号：2025-019 康芝药业股份有限公司 第六届监事会第十五次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 康芝药业股份有限公司（以下简称"康芝药业"或"公司"）第六届监事会 第十五次会议于 2025 年 4 月 25 日下午 16:30 在海口国家高新技术产业开发区 药谷工业园药谷三路 6 号公司会议室以现场表决的方式召开。会议通知于 2025 年 4 月 14 日分别以邮件、电话和书面的方式发出，应出席本次会议监事 3 名， 实际出席监事 3 名，符合《中华人民共和国公司法》《公司章程》等法律法规的 规定。本次会议由公司监事会主席高洪常先生主持。出席会议的全体监事经过认 真审议，通过了以下议案： 具体内容详见公司同日刊登在巨潮资讯网（www.cninfo.com.cn）等中国证 监会指定信息披露网站上的《2024 年度监事会工作报告》。 2、以 3 票赞同、0 票反对、0 票弃权审议通过了《2024 年年度报告及摘要》。 经审核，监事会认为：董事会编制和审核的《2024 年年度报告及摘要》，符 ...

证券代码：300086 证券简称：康芝药业 公告编号：2025-006 康芝药业股份有限公司 第六届董事会第十八次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 康芝药业股份有限公司（以下简称"公司"）第六届董事会第十八次会议于 2025 年 4 月 25 日下午 15:00 在海口国家高新技术产业开发区药谷工业园药谷三路 6 号 会议室以现场及通讯表决方式召开。会议通知于 2025 年 4 月 14 日分别以邮件、 电话等方式发出，应出席本次会议董事 9 名，实际出席董事 9 名。会议由董事长洪 江游先生主持，公司监事及相关高级管理人员列席了本次会议。会议的召开符合 《中华人民共和国公司法》《公司章程》等法律法规的规定。 1 经与会董事认真审议并表决，通过了以下议案： 1.以 9 票赞同、0 票反对、0 票弃权审议通过了《公司 2024 年度董事会工作报 告》。 公司报告期内任职的独立董事张继承先生、吴清和先生、郑欢雪先生及方灿辉 先生向董事会递交了《2024 年度独立董事述职报告》，并将在公司 2024 年度股东 大会上进行述职。董事会依据现任独立 ...

证券代码：300086 证券简称：康芝药业 告编号：2025-010 康芝药业股份有限公司 关于公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 4 月 25 日，康芝药业股份有限公司（以下简称"公司"）第六 届董事会第十八次会议、第六届监事会第十五次会议审议通过了《公司 2024 年度利润分配预案》，本议案尚需提交公司 2024 年年度股东大会审议，现将 有关情况公告如下： 一、2024 年度利润分配方案基本情况 经中审众环会计师事务所（特殊普通合伙人）审计，公司合并净利润为 -224,426,506.01元，其中归属于母公司所有者的净利润为-216,208,517.94 元。截至2024年12月31日，合并报表未分配利润为-264,867,579.44元，母公 司 报 表 未 分 配 利 润 为 -42,618,040.65 元 ， 合 并 资 本 公 积 余 额 为 842,991,008.41元。 根据《公司法》《公司章程》及《上市公司监管指引第3号--上市公司现 金分红》等相关法律法规的要求，利润分配应以 ...

证券代码：300086 证券简称：康芝药业 公告编号：2025-016 康芝药业股份有限公司 关于作废处理部分限制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 康芝药业股份有限公司（下称"康芝药业"或"公司"）于 2025 年 4 月 25 日召 开第六届董事会第十八次会议和第六届监事会第十五次会议，审议通过了《关于 作废处理部分限制性股票的议案》，现将有关事项说明如下： 一、公司 2023 年限制性股票激励计划已履行的决策程序和信息披露情况 1、2023 年 6 月 9 日，公司召开了第六届董事会第六次会议，审议通过《关 于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董 事会办理 2023 年限制性股票激励计划相关事宜的议案》等议案，公司独立董事 对本次股权激励计划的相关事项发表了独立意见。 同日，公司召开了第六届监事会第五次会议，审议通过了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年限制性 股 ...

康芝药业4月28日晚间披露了2024年年度报告及2025年第一季度报告。报告显示，2024年公司实现 营业 收入4.73亿元，归母 净利润-2.16亿元，报告期内，经营活动现金流净额同比增长1.08%，体现公司在销 售回款管理、库存管理、资金统筹等多方面资源优化配置的综合成效。2025年第一季度，康芝药业营业 收入达1.12亿元，归母净利润为-969万元，同比大幅减亏79.16%。对于业绩改善的原因，报告称是销售 费用同比减少，导致净利润亏损额减少。其中，一季度现金流量净额为4051万元，较上年同期上升 228.66%，原因是销售费用同比减少，以及收到控股股东汇来的拟履约款。 ...

Financial Performance - The company's operating revenue for 2024 decreased compared to 2023 due to inventory destocking and a decline in terminal sales volume [5]. - The company's operating revenue for 2024 was ¥472,817,734.83, a decrease of 36.07% compared to ¥739,569,815.25 in 2023 [23]. - The net profit attributable to shareholders for 2024 was -¥216,208,517.94, representing a significant decline of 1,975.20% from ¥11,529,863.15 in 2023 [23]. - The cash flow from operating activities for 2024 was ¥71,459,925.62, showing a slight increase of 1.08% from ¥70,693,705.92 in 2023 [23]. - The total assets at the end of 2024 were ¥1,975,850,549.69, down 8.76% from ¥2,165,626,241.76 at the end of 2023 [23]. - The basic earnings per share for 2024 was -¥0.4737, a decrease of 1,950.39% compared to ¥0.0256 in 2023 [23]. - The company reported a negative net profit for the last three accounting years, indicating ongoing uncertainty regarding its ability to continue as a going concern [23]. - Revenue after deducting non-operating income for 2024 was ¥457,667,622.31, compared to ¥727,732,362.19 in 2023, reflecting a significant decline [24]. - The company experienced a net loss of -¥93,477,729.25 in Q4 2024, with quarterly revenues showing fluctuations throughout the year [26]. - Children's medicine revenue reached ¥315,305,726.10, accounting for 66.69% of total revenue, with a year-on-year decrease of 35.25% [91]. - Adult medicine revenue was ¥80,522,755.11, representing 17.03% of total revenue, down 44.08% year-on-year [91]. - Medical device revenue increased by 20.03% year-on-year to ¥2,318,673.52, making up 0.49% of total revenue [91]. - Domestic revenue was ¥471,074,949.36, comprising 99.63% of total revenue, with a decline of 36.21% compared to the previous year [91]. - Total sales volume in the pharmaceutical sector decreased by 39.84% to 43,012,651 units, while production volume fell by 63.40% to 25,090,023 units [93]. - The gross profit margin for the pharmaceutical industry was 59.01%, down 4.11% year-on-year, with total revenue of ¥424,603,801.64 [92]. - Sales expenses increased by 23.39% to ¥262,699,679.67, while management expenses decreased by 16.50% to ¥116,627,969.25 [102]. Market and Industry Trends - The company has increased sales investment to enhance market share and expand marketing channels in response to intensified competition in the pharmaceutical market [5]. - The pharmaceutical industry continues to present new opportunities despite challenges, driven by factors such as economic growth and increasing healthcare demands [35]. - The Chinese government has implemented numerous favorable policies to support the development of traditional Chinese medicine (TCM), enhancing the industry's growth potential [36]. - In 2024, the National Health Commission plans to expand the application of TCM in health care for the elderly, addressing chronic diseases and promoting long-term growth opportunities in the TCM sector [36]. - The National Medical Products Administration has increased the number of pediatric drugs approved for market, with 23 new drug varieties added to the encouragement list in 2024, building on a previous total of 129 [39]. - The company anticipates intensified competition in the pharmaceutical industry, particularly in the children's medicine market, due to increasing capital influx [144]. Research and Development - The company has over 30 years of experience in the research, production, and sales of pediatric medicines, establishing a comprehensive product portfolio in the children's medication sector [41]. - The company has developed several core products, including Levosetirizine Granules and Itraconazole Dispersible Tablets, which occupy a significant market share in their respective fields [41]. - The company has established a research institute focused on pediatric medicine, with a high-education R&D team and collaborations with various pharmaceutical institutions [45]. - The company has developed 59 patents in China, including 56 for inventions and utility models, and 3 design patents, with one invention patent currently under application [49]. - The company has several R&D projects in clinical research aimed at enriching its product line, including Ibuprofen Deoxycorticosterone Tablets and Children's Dextromethorphan Hydrobromide Film [104]. - The company has received regulatory approvals for multiple products, including the Cephalosporin and Carbocisteine Syrup, enhancing its product offerings [105]. - R&D investment amounted to ¥26,378,873.07 in 2024, representing 5.58% of operating revenue, an increase from 3.38% in 2023 [106]. - The number of R&D personnel decreased by 15.32% from 111 in 2023 to 94 in 2024 [106]. Corporate Governance - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation of the board and protection of shareholder rights [151]. - The company held its annual general meeting, ensuring equal rights for all shareholders, particularly minority shareholders, to participate and vote on significant matters [152]. - The board consists of 9 members, including 4 independent directors, meeting the legal requirements for governance structure [153]. - The company has set up specialized committees within the board, with independent directors holding a majority in most committees, ensuring professional oversight [153]. - The company has not faced any unresolved governance issues or regulatory actions from authorities [151]. - The company is committed to enhancing its market value through a value enhancement plan, although specific details were not disclosed [148]. - The company has implemented a "Quality and Return Improvement" action plan, but details on its execution were not provided [149]. - The company is actively engaging with investors through various communication channels, including remote meetings and investor relations platforms [147]. - The company confirmed its independence from controlling shareholders in terms of assets, personnel, and operations, ensuring no conflicts of interest [158]. - The company has not engaged in any related party transactions or non-compliance issues during the reporting period [157]. Operational Efficiency - The company emphasizes internal management optimization, focusing on cost control and efficiency improvements to enhance operational performance [58]. - The company has implemented a centralized supply chain management system to optimize procurement and ensure timely supply of quality materials [53]. - The company has integrated product resources across its production bases to reduce costs and improve production efficiency [60]. - The company aims to enhance production efficiency and reduce costs by utilizing external production capabilities and technology transfers [133]. - The decision to halt the drug research center project was influenced by the strategic shift to relocate R&D to the Guangdong base, optimizing resource allocation [134]. Community Engagement and Social Responsibility - The company engaged in community support activities, including donating 5,300 books and 327 sets of school uniforms to a primary school in Guizhou Province [86]. - The company conducted disaster recovery efforts following Typhoon "Mojia," ensuring a swift return to normal operations at the Hainan production base [82]. Employee Relations - The company organized a skill competition to enhance employee professional skills and improve work quality and efficiency [83]. - The company has implemented an employee stock incentive plan, with 80 employees receiving a total of 5,124,411 restricted shares, set to be listed on October 14, 2024 [82]. - The company faces human resource risks due to intense competition for talent and aims to enhance employee retention through competitive compensation and stock incentives [146]. Environmental Compliance - The company emphasizes the importance of environmental protection and compliance with regulations in its operational strategies [145]. - The company emphasizes environmental protection and plans to increase investment in environmental facilities to comply with stricter regulations, which may impact operating profits [146].

Financial Performance - The company's operating revenue for Q1 2025 was ¥112,416,086.22, representing a 7.33% increase compared to ¥104,742,326.30 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥9,691,696.26, which is an improvement of 79.16% from a loss of ¥46,504,959.09 in the previous year[5] - Basic earnings per share improved by 79.38%, resulting in a loss of ¥0.0213 per share, compared to a loss of ¥0.1033 per share in the previous year[5] - The company reported a net loss of CNY 274,559,275.70, compared to a loss of CNY 264,867,579.44 in the previous period[15] - Net profit for the current period was -¥10,256,142.69, compared to -¥47,334,078.33 in the previous period, indicating a substantial improvement[18] Cash Flow and Assets - The net cash flow from operating activities increased by 228.66%, reaching ¥40,513,137.97, compared to a negative cash flow of ¥31,488,693.26 in the same period last year[5] - Cash flow from operating activities generated a net inflow of ¥40,513,137.97, contrasting with a net outflow of -¥31,488,693.26 in the previous period[21] - Cash and cash equivalents at the end of the period totaled ¥92,968,241.64, down from ¥114,288,937.74 at the end of the previous period[21] - Total assets at the end of the reporting period were ¥2,012,881,330.78, reflecting a 1.87% increase from ¥1,975,850,549.69 at the end of the previous year[5] - The company's total liabilities reached CNY 857,821,623.56, up from CNY 810,531,600.56, indicating a growth in financial obligations[15] Expenses and Cost Management - Total operating costs decreased to ¥126,233,165.07, down 17.87% from ¥153,590,745.48 in the previous period[17] - Sales expenses were reduced to ¥33,568,194.79, a decrease of 44.66% compared to ¥60,621,744.14 in the previous period[17] - Research and development expenses decreased to ¥2,848,491.65, down 38.67% from ¥4,640,407.51 in the previous period[18] - The increase in net profit attributable to shareholders was primarily due to a reduction in sales expenses, leading to a smaller loss[7] Shareholder and Equity Information - The equity attributable to shareholders decreased by 0.85%, amounting to ¥1,130,227,617.53 compared to ¥1,139,922,413.01 at the end of the previous year[5] - The top shareholder, Hainan Hongshi Investment Co., Ltd., holds 27.25% of the shares, with 95,900,000 shares pledged[10] Government Support and Strategic Initiatives - The company received government subsidies totaling ¥698,403.39 during the reporting period, contributing to its financial performance[6] - The company has successfully completed the registration of its expanded business scope, indicating strategic growth initiatives[12] - The company received CNY 1,000,000 in land compensation and paid CNY 46,213,401.6 for land use change, reflecting ongoing asset management strategies[12] - The company is actively involved in digital transformation projects, which have been recognized by local government initiatives[12] - The company has initiated a health project aimed at improving women's health, demonstrating its commitment to social responsibility[12] Inventory and Receivables - Accounts receivable decreased to CNY 55,223,350.21 from CNY 68,444,816.20, a reduction of about 19.3%[13] - Inventory levels decreased to CNY 175,431,076.57 from CNY 187,328,641.20, showing a decline of approximately 6.4%[14] Non-Recurring Losses - The company reported a significant reduction in non-recurring losses, with a total of ¥1,019,778.64 recognized in the current period[6]